133 related articles for article (PubMed ID: 7003455)
1. Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Vogl SE; Lanham R; Kaplan BH
Oncology; 1980; 37(5):314-5. PubMed ID: 7003455
[TBL] [Abstract][Full Text] [Related]
2. Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
Vogl SE; Qazi R; Berenzweig M
Cancer Treat Rep; 1980; 64(10-11):1143-5. PubMed ID: 7459902
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma.
McCreary RH; Moertel CG; Schutt AJ; O'Connell MJ; Hahn RG; Reitemeier RJ; Rubin J; Frytak S
Cancer; 1977 Jul; 40(1):9-13. PubMed ID: 141977
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma.
Paul AR; Catalano RB; Engstrom PF
Cancer Treat Rep; 1980; 64(10-11):1047-9. PubMed ID: 7006805
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
Windschitl HE; Krook JE; Everson LK; Cullinan SA; Scott M
Cancer Treat Rep; 1982 Dec; 66(12):2093-4. PubMed ID: 7139652
[No Abstract] [Full Text] [Related]
7. A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
O'Connell MJ; Schutt AJ; Moertel CG; Rubin J; Hahn RG; Scott M
Am J Clin Oncol; 1987 Aug; 10(4):320-4. PubMed ID: 3303905
[TBL] [Abstract][Full Text] [Related]
8. ICRF-159: current status and clinical prospects.
Bellet RE; Rozencweig M; Von Hoff DD; Penta JS; Wasserman TH; Muggia FM
Eur J Cancer (1965); 1977 Nov; 13(11):1293-8. PubMed ID: 590286
[No Abstract] [Full Text] [Related]
9. Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma.
Marciniak TA; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
Cancer Chemother Rep; 1975; 59(4):761-3. PubMed ID: 1100228
[No Abstract] [Full Text] [Related]
10. Phase II study of Baker's antifol in advanced colorectal cancer.
Padilla F; Correa J; Buroker T; Vaitkevicius VK
Cancer Treat Rep; 1978 Apr; 62(4):553-4. PubMed ID: 350391
[No Abstract] [Full Text] [Related]
11. Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Kemeny NE; Ahmed T; Michaelson RA; Harper HD; Yip LC
J Clin Oncol; 1984 Apr; 2(4):311-5. PubMed ID: 6200577
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy.
Bellet RE; Engstrom PF; Catalano RB; Creech RH; Mastrangelo MJ
Cancer Treat Rep; 1976 Sep; 60(9):1395-7. PubMed ID: 1016973
[No Abstract] [Full Text] [Related]
13. A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Gilbert JM; Cassell PC; Ellis H; Wastell C; Hellmann K; Evans MG; Stoodley BJ
Recent Results Cancer Res; 1981; 79():48-58. PubMed ID: 7029684
[TBL] [Abstract][Full Text] [Related]
14. A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Smith BJ; Ashford RF; Bakowski M; Hellman K; Newton K; Phillips R; Lambert J; Jones R; Peters N; Evans M
Am J Clin Oncol; 1983 Aug; 6(4):481-4. PubMed ID: 6346856
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five-year follow-up.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Taylor RH; Stoodley B; Ellis H; Wastell C
Br J Surg; 1986 Jun; 73(6):446-50. PubMed ID: 3521784
[TBL] [Abstract][Full Text] [Related]
16. ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.
Conroy JF; Lewis GC; Blessing JA; Mangan C; Hatch K; Wilbanks G
Am J Clin Oncol; 1984 Apr; 7(2):131-3. PubMed ID: 6702716
[TBL] [Abstract][Full Text] [Related]
17. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
[TBL] [Abstract][Full Text] [Related]
18. A trial of razoxane (ICRF-159) in patients with prior therapy for Hodgkin's lymphoma.
Corder MP; McFadden DB; Bell SJ
Cancer; 1984 Oct; 54(8):1496-8. PubMed ID: 6383594
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant oral razoxane (ICRF-159) in resectable colorectal cancer.
Gilbert JM; Hellmann K; Evans M; Cassell PG; Stoodley B; Ellis H; Wastell C
Cancer Chemother Pharmacol; 1982; 8(3):293-9. PubMed ID: 7127660
[TBL] [Abstract][Full Text] [Related]
20. Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Cedermark BJ; Kaufman JH; Douglass HO; Mittelman A
Clin Oncol; 1977 Mar; 3(1):27-31. PubMed ID: 862274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
